{"id":726076,"date":"2023-01-26T08:03:09","date_gmt":"2023-01-26T13:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/"},"modified":"2023-01-26T08:03:09","modified_gmt":"2023-01-26T13:03:09","slug":"ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/","title":{"rendered":"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LEXINGTON, Mass., Jan.  26, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XY0xTsWiRQO6acaCCKEG10KhZDjd8MubOSQkoDZYvwFQe2uhj78kGVJgnPtMZZ1Mc5uHDA7xWALI2qsZZEqm0Q==\" rel=\"nofollow noopener\" target=\"_blank\">iVexSol<\/a> Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of more than $39 million.<\/p>\n<p align=\"justify\">The new funding will be used to invest in iVexSol\u2019s Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines.<\/p>\n<p align=\"justify\">\u201cCurrent vector production methods continue to struggle to meet clinical and commercial demand,\u201d remarked Dr. Rodney Rietze, iVexSol co-founder and CEO. \u201cOur cost-effective and highly scalable Intelligent Vector Solutions are designed to break the vector supply bottleneck and provide greater access to patients seeking life-saving treatments. Receiving support from industry leaders Bristol Myers Squib and Charles River Laboratories, along with new entrants like Asahi Kasei Medical is transformative, enabling us to advance our production capabilities and provide a more comprehensive offering to our clients.\u201d<\/p>\n<p align=\"justify\">iVexSol\u2019s Intelligent Vector Solutions revolutionize the production of LVVs \u2013 gene delivery vehicles that are a critical raw material in the manufacturing of life-changing cell and gene therapies (CGTs). The technology platform uses banks of vector-producing cells to reliably produce LVV at significantly greater quantities than current approaches and facilitate the rapid scale-out needed for global demand, all within a smaller manufacturing footprint. These advances enable shorter clinical development timelines, reduced costs, and ultimately, increased global access for patients waiting to receive these transformative medicines.<\/p>\n<p align=\"justify\">The company is currently focused on generating stable LVV cell lines using each client\u2019s gene of interest, to enable a robust and readily available supply of \u201con-demand\u201d vector to meet the client\u2019s growing vector needs.<\/p>\n<p>\n        <strong>About iVexSol<br \/><\/strong>iVexSol, Inc. is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made. Its technology will greatly reduce the complexity, cost, and development time of these critical reagents, thereby accelerating the development and enabling greater access to life-changing cell and gene therapies. For more information visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ueGpSh4JhvOYJJ1zUR9XWPciMXuEvzYjE9D9DFKdmoAtXsRB3u6jytWWYWoGhueUEGyUK7TBcZPiyMqJcg6l9w==\" rel=\"nofollow noopener\" target=\"_blank\">www.ivexsol.com<\/a>.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Mzk1ZTVhNTEtODFjNS00ZTcyLTlkNGItOGJhYTIzMzFhMmYwLTUwMDA2ODQ2Nw==\/tiny\/iVexSol.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Media Contact:\r\nTim Walsh\r\nfor iVexSol\r\n617.512.1641\r\ntimw@walshgroupmarketing.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) &#8212; iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of more than $39 million. The new funding will be used to invest in iVexSol\u2019s Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines. \u201cCurrent vector &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726076","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) &#8212; iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of more than $39 million. The new funding will be used to invest in iVexSol\u2019s Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines. \u201cCurrent vector &hellip; Continue reading &quot;iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-26T13:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors\",\"datePublished\":\"2023-01-26T13:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/\"},\"wordCount\":401,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/\",\"name\":\"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==\",\"datePublished\":\"2023-01-26T13:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/","og_locale":"en_US","og_type":"article","og_title":"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors - Market Newsdesk","og_description":"LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) &#8212; iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of more than $39 million. The new funding will be used to invest in iVexSol\u2019s Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines. \u201cCurrent vector &hellip; Continue reading \"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-26T13:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors","datePublished":"2023-01-26T13:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/"},"wordCount":401,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/","name":"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==","datePublished":"2023-01-26T13:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNzA1MCM1Mzc1ODQwIzUwMDA2ODQ2Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ivexsol-closes-23-8m-series-a-3-financing-funds-to-revolutionize-the-production-of-lentiviral-vectors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iVexSol\u00ae Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726076"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726076\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}